Triphala as an antimicrobial: a critical appraisal of the evidence from metabolites and mechanisms to clinical trials
Year: 2026
Type: article
Abstract: Introduction Triphala, an Ayurvedic formulation of three botanical drugs rich in plant metabolites, is proposed as an antimicrobial and as an adjunct against antimicrobial resistance. Earlier reviews catalogue its activity but do not test how well the evidence supports these claims. Methods This critical narrative review appraises the strength and validity of the evidence for the antimicrobial activity of Triphala, from metabolites and mechanisms to clinical trials. Studies identified in PubMed, Scopus, Web of Science and Google Scholar (searched on 01 June 2026, with additions up to 17 October 2026) were classified by model type and by the material tested (whole Triphala, single botanical drugs, isolated metabolites), graded on a six-level scale, and appraised for assay validity, reported synergy against the conventional fractional inhibitory concentration index criterion of 0.5 or less, achievable exposure and trial quality. Results Crude extracts inhibit Gram-positive and Gram-negative bacteria in vitro , mostly at minimum inhibitory concentrations above 1,000 μg/mL (lowest 276 μg/mL), and reduce biofilm formation and virulence in selected models, but no proposed mechanism has been shown for a defined whole-Triphala preparation. Lower gentamicin and oxacillin minimum inhibitory concentrations were reported at a fractional inhibitory concentration index below 1; under the conventional criterion (0.5 or less), 9 of 17 isolate–antibiotic combinations and 6 of 25 extract combinations met the synergy definition, but only in single checkerboard studies without independent confirmation, so the findings are best described as combination effects. Estimated concentrations reach or exceed the lower minimum inhibitory concentrations in the mouth and gut lumen but not in plasma, so systemic activity is not supported. Human evidence comes from small, short randomised trials of mouth rinses (ten of twelve clinical studies are dental), with effects comparable to chlorhexidine in individual trials and high heterogeneity in pooled analyses; none addresses systemic, gastrointestinal or skin infection or use with antibiotics. Discussion Current evidence supports Triphala, at most, as a candidate local antimicrobial, and not as a treatment for systemic or gastrointestinal infection or as an antibiotic adjunct. Future studies should prioritise standardised preparations, controlled in vitro assays, exposure and interaction studies, and larger randomised trials.
Source: Frontiers in Pharmacology
Authors: Riya Patel(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Vivekanand Ankush Kashid(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Pankaj Bansal(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Chadarat Ampasavate(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Chuda Chittasupho(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Sudarshan Singh(Data curation, Methodology, Resources, Validation, Visualization, Writing – original draft), Bhupendra Gopalbhai Prajapati(Conceptualization, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing), Wasan Katip(Conceptualization, Methodology, Resources, Validation, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Food Science
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235634416
